title: One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
abstract: BACKGROUND
  The Taxus Olympia registry is a prospective, postapproval registry collecting clinical outcomes data on patients receiving the Taxus Liberté paclitaxel-eluting stent during routine interventional cardiology practice.
  
  
  METHODS
  Between February and July 2005, 529 patients receiving the Taxus Liberté stent at 16 centers in the Middle East, South/Central America, and Asia/Pacific regions were enrolled in Phase I of Olympia. The primary end-point was Taxus Liberté stent-related cardiac events (cardiac death, MI, and revascularization) at 30 days postimplant. Additional clinical assessment was conducted at 6 and 12 months. Olympia phases II and III are in clinical follow-up and will be reported separately.
  
  
  RESULTS
  One-year clinical follow-up is available for 98% of patients. Complex patients and lesions were prevalent, including: 50% diabetes mellitus, 49% multivessel disease, 30% multiple stenting, 48% AHA/ACC type B2/C lesions, 19% long lesions (>26 mm), and 40% small vessels (<or=2.75 mm). At 1 year, the cardiac event rate was 4.1%, including 1.5% cardiac death, 1.5% MI, and 2.3% target vessel revascularization (TVR). The TAXUS Liberté stent-related cardiac event rate was 3.7% at 1 year. Stent thrombosis (ST) occurred in 1.7% of patients, with three cases occurring >30 days postprocedure. One-year cardiac event rates among complex subpopulations (diabetics 5.0%, multiple stents 3.8%, long lesions 3.1%, and small vessels 2.9%) were comparable to the overall study population.
  
  
  CONCLUSIONS
  In conclusion, this first report of real-world experience with the Taxus Liberté stent demonstrates the safety and clinical utility of this stent in the broader spectrum of coronary disease treated in everyday practice.
authors.affiliation: Armed Forces Hospital, Jeddah, Saudi Arabia. waqar@post.harvard.edu
authors.forename: Waqar Habib
authors.initials: WH
authors.lastname: Ahmed
authors.forename: Robaayah
authors.initials: R
authors.lastname: Zambahari
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Al-Rashdan
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al Naeemi
authors.forename: Fuad A
authors.initials: FA
authors.lastname: Saeed
authors.forename: Stephen
authors.initials: S
authors.lastname: Mascioli
mesh_terms: D000328:Adult; D000368:Aged; D000800:Angioplasty, Balloon; D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000706:statistics & numerical data*; D001208:Asia / Q000453:epidemiology; D006328:Cardiac Catheterization; D002489:Central America / Q000453:epidemiology; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008877:Middle East / Q000453:epidemiology; D009203:Myocardial Infarction / Q000401:mortality; D009204:Myocardial Revascularization / Q000379:methods / Q000706:statistics & numerical data*; D017239:Paclitaxel / Q000008:administration & dosage*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012042:Registries; D013020:South America / Q000453:epidemiology; D020946:Taxus; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage*
chemical_list: D050257:Tubulin Modulators; D017239:Paclitaxel